Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ALT
#2852
Altimmune, Inc. - Common Stock
2.5
6
USD
-0.02%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.92%
Monthly Change
-21.71%
6 month change
-21.23%
Year Change
-34.69%
Previous Close
2.6
1
Open
2.5
9
Low
2.5
6
High
2.6
3
Markets
US Stock Market
Healthcare
Biotechnology
ALT
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
37.15 M
43.22 M
49.28 M
70.9 M
77.01 M
130.07 M
194.52 M
Valuation ratios
Enterprise value
304.97 M
207.07 M
663.71 M
610.7 M
518.34 M
460.08 M
470.67 M
Price to earnings ratio
—
-3.9
-8.64
-6.34
-5.38
-3.61
-3.33
Price to sales ratio
—
85.74
10.79 K
1 314.92
25.6 K
7 757.46
-2 552.39
Price to cash flow ratio
—
-4.83
11.72
7.39
6.41
-4.71
-3.93
Price to book ratio
—
1.9
3.96
2.89
4.14
1.41
0.27
Enterprise value to EBITDA ratio
-5.6
-2.15
-7.61
-6.24
-4.85
-4.78
-4.59
Profitability ratios
Return on assets %
-0.2
-0.44
-0.41
-0.42
-0.68
-0.31
-0.04
Return on equity %
-0.22
-0.49
-0.46
-0.46
-0.77
-0.39
-0.05
Return on invested capital %
-1 240.11
-1 610.96
-1 362.31
-2 511.47
—
-4 628.61
-102.04
Gross margin %
100
100
100
100
100
100
100
Operating margin %
-669.5
-2 197.42
129.03 K
-22.52 K
-515.86 K
-230.46 K
119.22 K
EBITDA margin %
-665.86
-2 184.92
128.29 K
-22.99 K
-533.92 K
-234.73 K
122.61 K
Net margin %
-599.2
-2 201.43
124.58 K
-20.76 K
-475.29 K
-214.86 K
103.75 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
19.16
11.17
11.31
17.26
13.11
18.55
26.78
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.05
0.02
-0
0
0
0
-0
Solvency ratios
Debt to assets ratio
0.01
0.01
0.02
—
—
0.12
0.07
Debt to equity ratio
0.01
0.01
0.02
—
—
0.15
0.07
Long term debt to total assets ratio
0.01
0.01
0.02
—
—
0.12
0.07
Long term debt to total equity ratio
0.01
0.01
0.02
—
—
0.15
0.07
Per share metrics
Operating cash flow per share
—
-1.9
-1.33
-1.42
-1.12
-0.77
-0.65
EBIT per share
—
-2.35
-1.87
-1.8
-1.45
-1.07
-0.9
EBITDA per share
—
-2.33
-1.86
-1.84
-1.5
-1.09
-0.92
Total debt per share
—
0.04
0.1
—
—
0.39
0.19
Cash per share
—
4.61
3.94
3.72
1.86
3.1
1.76
Net current asset value per share
—
4.94
4.11
3.94
1.93
3.16
1.81
Tangible book value per share
—
4.82
3.95
3.65
1.74
2.55
2.56
Working capital per share
—
4.5
3.75
3.71
1.79
2.99
1.74
Book value per share
—
4.82
3.95
3.65
1.74
2.55
2.56
News
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care?
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
3 Under $10 Stocks With 150%+ Upside to Buy in September 2026, According to Analysts - TipRanks.com
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised